Medical/Pharmaceuticals Global News & Press Release Distribution

Medical/Pharmaceuticals

All
APAC

Clarity expands its pipeline with a novel optimised FAP-targeted radiopharmaceutical

Highlights * Clarity has developed a proprietary fibroblast activation protein (FAP)-targeted radiopharmaceutical product that can be used with the perfect pairing of copper isotopes for the diagnosis and treatment of cancer. * The product, termed SAR-bisFAP, has shown strong tumour targeting...

2024-12-18 22:03 3121

Juncell Therapeutics Opens State-of-the-Art Facility for TIL Production

SHANGHAI, Dec. 18, 2024 /PRNewswire/ -- Shanghai Juncell Therapeutics Co., Ltd. (Juncell Therapeutics), a clinical-stage biotech focused on innovative IL-2-independent Tumor-Infiltrating Lymphocyte (TIL) therapies, announced the grand opening of its state-of-the-art TIL manufacturing facility loc...

2024-12-18 21:08 2458

Samsung invests in Generate: Biomedicines to advance AI-driven protein therapeutics discovery

- Samsung Life Science Fund invests in Generate:Biomedicines, a Flagship Pioneering company leading in AI-enabled protein therapeutics discovery and development - Investment highlights Samsung's dedication to advancing innovation and creating a robust ecosystem for AI-enabled therapeutic develop...

2024-12-18 13:09 5277

U.S. FDA approves Celltrion's STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab)

* STEQEYMA (CT-P43) is approved for both adult and pediatric patients with plaque psoriasis (PsO) and active psoriatic arthritis (PsA) as well as adults with Crohn's disease (CD) and ulcerative colitis (UC) * STEQEYMA is a strategic addition to Celltrion's portfolio, expanding the portfolio a...

2024-12-18 11:50 2293

Ubie Growth in 2024 Driven by Industry Leading Recognition, Collaborations with Patient Advocacy Groups and an Expanded Reach of More Than 4 Million Users

* Strategic investment from Google and acceptance into Mayo Clinic Platform Accelerate program show an increasing understanding of Ubie's value to patients and healthcare * Key platform innovations have led to increased user engagement, with a 30% increase in call to action engagement * Res...

2024-12-17 22:30 4024

Complete Genomics Adds Eurofins Clinical Enterprise, LLC to its Sequencing Service Provider Program

FRAMINGHAM, Mass., Dec. 17, 2024 /PRNewswire/ -- Complete Genomics, a San Jose, California based genomics tools manufacturer, today announced Framingham, Massachusetts based Eurofins Clinical Enterprise, LLC as the newest addition to its Sequencing Service Provider Program. Complete Genomics'...

2024-12-17 22:00 2168

Lakeside Signs $1.5 Million Sales Agreement with Sinopharm Group Subsidiary

Agreement to Deliver Critical Medicines ITASCA, Ill., Dec. 17, 2024 /PRNewswire/ -- Lakeside Holding Limited ("Lakeside" or the "Company") (Nasdaq: LSH), a U.S.-based cross-border supply chain solution provider with a unique focus on theAsia-Pacific market is pleased to announce that Hupan Phar...

2024-12-17 21:30 2788

Fangzhou Inc. Recognized as an "Outstanding Enterprise in Digital Intelligence" by Analysys Star

HANGZHOU, China, Dec. 17, 2024 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, was recognized as an "Outstanding Enterprise in Digital Intelligence" on the "Analysys Star 2024 Annual Award List" (releasedDecember 10th), alongside ...

2024-12-17 17:26 2488

Great Bay Bio Completes First Close of Series B Financing

HONG KONG, Dec. 17, 2024 /PRNewswire/ -- Great Bay Bio (GBB) is thrilled to announce the successful first close of its Series B financing round. This milestone was achieved with the round led by a syndication of a well-known strategic investment institution and its affiliate, Tiger Jade Pebble A...

2024-12-17 16:42 3019

Great Bay Bio Completes First Close of Series B Financing

SK Biopharmaceuticals Inks Research Collaboration Agreement with ProEn Therapeutics Further Accelerating Expansion of Oncology Research and Pipeline for Global Competitiveness in Radiopharmaceuticals

SK Biopharmaceuticals, ProEn Therapeutics aim to advance up to 2 preclinical radiopharmaceutical candidates by 2027, via ArtBody™, a bivalent binder platform designed to selectively target tumor cells SK Biopharmaceuticals eyes innovative small protein-based radiopharmaceuticals on safety and ef...

2024-12-17 08:20 2876

Samsung Biologics listed among top most sustainable companies in Dow Jones Sustainability World Index

* Acknowledged for strong environmental, social, and governance (ESG) performance and continued commitment to sustainability through net-zero initiatives and responsible value chain management INCHEON, South Korea, Dec. 16, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contr...

2024-12-17 07:51 3242

Microbio Co., Ltd. (4128) Announces Promising Results of "MS-20" in Combination with Keytruda for Stage IIIb/IV Non-Small Cell Lung Cancer

CUPERTINO, Calif., Dec. 16, 2024 /PRNewswire/ -- Microbio Co., Ltd. (4128) today revealed encouraging results from an exploratory clinical trial of MS-20 combined with Keytruda (pembrolizumab) in stage IIIb/IV non-small cell lung cancer (NSCLC). The trial showed a threefold increase in the object...

2024-12-17 02:05 2232

Nona Biosciences Announces Discovery Collaboration with Candid Therapeutics for Next-Generation T-Cell Engagers

CAMBRIDGE, Mass., Dec. 16, 2024 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM ), today announced a research collaboration and license agreement to discover next-generation T-cell engagers ("TCEs") with Candid Therapeutics, ...

2024-12-16 20:03 2060

Fangzhou Inc. Garners Prestigious "Most Valued Pharmaceutical & Healthcare Enterprise" Award

SHENZHEN, China, Dec. 16, 2024 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, was honored with a "Most Valued Pharmaceutical & Healthcare Enterprise" award at the grand "9th Zhitong Finance Capital Market Summit and Listed Compan...

2024-12-16 18:13 2590

China Pharma Announces the Entry of "At-The-Market" Equity Offering

HAIKOU, China, Dec. 13, 2024 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," or the "Company"), a specialty pharmaceutical company, today announced that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission (the "SEC") under which...

2024-12-13 21:00 5365

Accropeutics Inc. Announces U.S. FDA Clearance of IND Application for RIPK2 Inhibitor AC-101

* Company to conduct a Phase II multi-regional clinical trial (MRCT) for the treatment of Ulcerative Colitis (UC) * A Phase Ib Study of AC-101 for Ulcerative Colitis (UC) has been initiated in China * AC-101 demonstrated a favorable safety and PK/PD profile in healthy volunteers in Phase Ia ...

2024-12-13 12:57 3579

Transcenta Debuts Promising Anti-Tumor Activity of Novel LIV-1 Targeting ADCs with Site-Specific Conjugated Topo I Inhibitor Payload in TNBC Tumor Models at 2024 SABCS

PRINCETON, N.J. and SUZHOU, China, Dec. 12, 2024 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, ann...

2024-12-13 08:00 2908

2024 SABCS｜Results Unveiled for the Phase III Study of Disitamab Vedotin in Treating HER2-Positive Advanced Breast Cancer with Liver Metastasis

YANTAI, China, Dec. 12, 2024 /PRNewswire/ -- On the morning of December 12, 2024 (UTC-6), at the Poster Spotlight Session "Novel HER2 Therapeutics" of the 47th San Antonio Breast Cancer Symposium (SABCS),RemeGen Co. Ltd. ("RemeGen") (9995.HK, 688331.SH) presented for the first time the data from ...

2024-12-13 07:20 3667

New Lunit Study Demonstrates Universal AI Model for Analysis of Immunohistochemistry Images

Research in npj Precision Oncology highlights multi-cohort training approach and accurate analysis of unseen immunohistochemistry data SEOUL, South Korea, Dec. 12, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, toda...

2024-12-12 22:08 3183

New Lunit Study Demonstrates Universal AI Model for Analysis of Immunohistochemistry Images

CureGene Received Clinical Trial Approval in China for CG-0255 for Injection - A Novel Antiplatelet Therapy

SHANGHAI, Dec. 12, 2024 /PRNewswire/ -- CureGene Pharmaceutical ("CureGene"), a biotechnology company dedicated to innovative treatments for critical unmet medical needs in cardio-cerebrovascular and antiviral disease, proudly announces the approval of its Clinical Trial Application by theChina's...

2024-12-12 21:00 3085

1 ... 99 100 101102103 104 105 ... 263